EP Patent

EP2368550A1 — Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Assigned to University of California · Expires 2011-09-28 · 15y expired

What this patent protects

A hydantoin compound according to formula II, wherein R 2 and R 3 form a cycle together with the carbon to which they are linked, useful for the prevention or treatment of hyperproliferative diseases or disorders.

USPTO Abstract

A hydantoin compound according to formula II, wherein R 2 and R 3 form a cycle together with the carbon to which they are linked, useful for the prevention or treatment of hyperproliferative diseases or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP2368550A1
Jurisdiction
EP
Classification
—
Expires
2011-09-28
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.